Bronchodilator

DISEASE PROFILE Date Assigned to Patient: 9/14/2011 Name of Major Medical Diagnosis: Chronic Obstructive Pulmonary Disease (COPD) Definition: COPD is a progressive disease that makes it hard to breathe. "Progressive" means the disease get worse over time. It can cause coughing that produces large amount of mucus, wheezing, shortness of breath, chest tightness, and other symptoms. Etiology: Most cases of COPD occur as a result of long-term exposure to lung irritants that damage

I would explain to Sarah’s mother that although there is no solid evidence demonstrate that tolerance may develop to the bronchodilator effects of Salbutamol [3], there are many studies supported that regular use of β2 agonists include Salbutamol lead to tolerance to their bronchodilator effects. [1][2][4][5][6] The main hypothesis of tolerance from regular use of salbutamol is associated with desensitisation of β2 adrenoceptor on the airway smooth muscle. [1][4][6] It is a protective mechanism

products is guaifenesin. Adequate water intake is important when taking an expectorant as it will assist in its effect (Kee, et al., 2012) What medications do you anticipate the physician ordering? Why? I would anticipate the physician ordering a bronchodilator like albuterol due to its rapid effectiveness in widening D.Q.’s airway. Additionally the physician could order an expectorant such as guaifenesin. Finally, a glucocorticoid, such as advair would most likely be prescribed to assist

June. Since discharge, she states that she has done well. She has stable dyspnea on exertion. She does feel that perhaps it might be slightly worse given the heat and humidity. She is not complaining of any cough. She is compliant with her bronchodilator regimen. She also carries a diagnosis of vocal cord dysfunction, obstructive sleep apnea, as well as tracheobronchomalacia. She states that she does try to remain as active as possible. She does participate in aquatic exercises at the YMCA

Pharmacological management includes the use of bronchodilators. The latest bronchodilator Anoro Ellipta seeks to manage COPD while simultaneously improving patient compliance. To understand the role of pharmacological treatment it is important to understand the fundamentals of COPD. What is COPD? Chronic Obstructive

Asthma is a lung disease that affects approximately ten million people in the United States. (Cramer 2) In people with asthma, the airways of the lungs are hypersensitive to irritants such as cigarette smoke or allergens. When these irritants are inhaled, the airways react by constricting, or narrowing. Some people with asthma have only mild, intermittent symptoms that can be controlled without drugs. In others, the symptoms are chronic, severe, and sometime life threatening. Although researchers

Clinical Intervention Presentation With chronic obstructive pulmonary disorder being the third leading cause of death in the United States annually, COPD is undoubtedly a growing epidemic. This disease develops slowly and progressively worsens over time. In the earliest stages of disease, symptoms may be minimal or non-existent. This complicates the implementation of early prevention and treatment strategies. Therefore, becoming aware of personal risk factors and possible genetic and environmental

production in the airways, as a result, the airways are less sensitive and less likely to react to asthmatic triggers that cause asthma attacks. Bronchodilators are medications that relieve symptoms of asthma by relaxing the muscles that tighten around the airways. The two types of bronchodilators are long-acting and short-acting. Short-acting bronchodilators are often referred to as rescue inhalers and are used to quickly relieve coughing, wheezing, chest tightness and shortness of breath caused by

“Tens of millions of people around the world find it distressingly difficult to breathe owing to a combination of emphysema and chronic asthmatic bronchitis – a deadly duo known as chronic obstructive pulmonary disease (COPD) (Brody, 2012).” The overall disease-state, role of exercise, treatments, and implications are all interrelated when improving patient COPD. Throughout this paper, all will be addressed with the goal to better the understanding of COPD. COPD is becoming prevalent disease within

The head, ear, eyes, nose, and throat (HEENT) are common sources of complaints seen amongst pediatric patients, particularly during the winter season, and the flu season. The common infections involving the HEENT are pharyngitis, strep throat, rhinitis, sinusitis, otitis media and externa, and conjunctivitis. The American Academy of Pediatrics (2013), has suggested the route of treatment that practitioners should elect when treating these conditions. It is suggested that no antibiotics be prescribed